See more : Kwong Lung Enterprise Co., Ltd. (8916.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of RepliCel Life Sciences Inc. (REPCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RepliCel Life Sciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Exploits Discovery Corp. (NFLDF) Income Statement Analysis – Financial Results
- Taiwan Auto-Design Co. (6791.TWO) Income Statement Analysis – Financial Results
- Pyramid AG (M3BK.DE) Income Statement Analysis – Financial Results
- Dinglong Culture Co., Ltd. (002502.SZ) Income Statement Analysis – Financial Results
- Greenland Resort Company Limited (9656.T) Income Statement Analysis – Financial Results
RepliCel Life Sciences Inc. (REPCF)
About RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 353.74K | 353.74K | 353.74K | 353.74K | 353.74K | 121.11K | 0.00 | 0.00 | 0.00 | 0.00 | 4.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.16K | 5.78K | 6.98K | 0.00 | 0.00 | 0.00 | 0.00 | 367.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 352.26K | 353.74K | 353.74K | 353.74K | 353.74K | 121.11K | -4.16K | -5.78K | -6.98K | 0.00 | 4.12M | 0.00 | 0.00 | -367.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.58% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 526.43K | 623.96K | 1.15M | 819.40K | 2.20M | 709.26K | 2.54M | 1.12M | 2.32M | 1.94M | 1.56M | 735.17K | 381.76K | 182.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.21M | 1.13M | 1.51M | 884.70K | 1.08M | 2.15M | 3.45M | 3.17M | 2.73M | 3.27M | 2.18M | 2.97M | 2.88M | 1.79M | 139.44K | 135.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.10K | 464.81K | 57.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.21M | 1.13M | 1.51M | 884.70K | 1.08M | 2.15M | 3.45M | 3.17M | 2.73M | 3.27M | 2.18M | 3.73M | 3.34M | 1.85M | 139.44K | 135.21K | 371.13K | 491.31K | 299.92K | 518.98K | 93.96K |
| Other Expenses | 0.00 | -2.82K | -2.82K | -22.11K | -33.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.08K | 7.59K | 6.94K | 0.00 | 0.00 | 371.13K | 491.31K | 299.92K | 518.98K | 93.96K |
| Operating Expenses | 517.10K | 1.75M | 2.65M | 1.68M | 3.28M | 2.86M | 5.99M | 4.29M | 5.05M | 5.21M | 3.74M | 4.47M | 3.73M | 2.04M | 139.44K | 135.21K | 371.13K | 491.31K | 299.92K | 518.98K | 93.96K |
| Cost & Expenses | 517.10K | 1.75M | 2.65M | 1.68M | 3.28M | 2.86M | 5.99M | 4.29M | 5.05M | 5.21M | 3.74M | 4.47M | 3.73M | 2.40M | 139.44K | 135.21K | 371.13K | 491.31K | 299.92K | 518.98K | 93.96K |
| Interest Income | 727.00 | 43.00 | 69.00 | 358.00 | 33.29K | 37.00 | 6.78K | 0.00 | 14.73K | 16.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 864.53 | 5.03K | 92.91 | 151.47 | 25.94 |
| Interest Expense | 149.10K | 6.70K | 5.53K | 176.09K | 141.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 565.00 | 701.00 | 1.59K | 63.07K | 137.71K | 153.58K | 8.93K |
| Depreciation & Amortization | 1.47K | 839.00 | 1.15K | 1.57K | 2.17K | 3.00K | 4.16K | 5.78K | 6.98K | 7.61K | 6.13K | 6.08K | 7.59K | 6.94K | -219.10K | 35.06K | 463.57K | -526.34K | 111.24K | 885.37K | 9.75K |
| EBITDA | -1.38M | -735.69K | -3.17M | -1.35M | -2.92M | -2.69M | 0.00 | 0.00 | -5.03M | -5.20M | 540.14K | 0.00 | -3.71M | 0.00 | -359.11K | -100.86K | -141.81K | -750.22K | -246.23K | -207.00K | -91.76K |
| EBITDA Ratio | -391.47% | -53.88% | -896.35% | -323.07% | -814.35% | -2,234.66% | 0.00% | 0.00% | 0.00% | 0.00% | 9.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.39M | -191.44K | -3.17M | -1.14M | -2.88M | -2.74M | -5.99M | -4.29M | -5.05M | -5.21M | 383.23K | -4.47M | -3.69M | -2.40M | -140.01K | -135.92K | -605.38K | -223.88K | -357.47K | -1.09M | -101.51K |
| Operating Income Ratio | -391.89% | -54.12% | -896.67% | -323.51% | -814.96% | -2,261.75% | 0.00% | 0.00% | 0.00% | 0.00% | 9.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.07M | 649.47K | -901.48K | -229.91K | -77.32K | -86.46K | -22.42K | 16.33K | 2.91K | 12.21K | 240.00 | 1.11M | -19.50K | 0.00 | 219.66K | -34.36K | 4.19K | -66.56K | -133.76K | -311.99K | -2.20K |
| Income Before Tax | -311.73K | -743.23K | -4.07M | -1.58M | -3.00M | -2.77M | -6.01M | -4.27M | -5.04M | -5.20M | 383.47K | -3.36M | -3.71M | -2.40M | 79.66K | -170.27K | -601.19K | -290.44K | -491.24K | -1.40M | -103.71K |
| Income Before Tax Ratio | -88.13% | -210.11% | -1,151.52% | -446.74% | -849.27% | -2,286.34% | 0.00% | 0.00% | 0.00% | 0.00% | 9.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 545.09K | -867.89K | 183.53K | 44.03K | -29.78K | 22.42K | -16.33K | -2.91K | -12.21K | 412.04K | -1.11M | -239.37K | 0.00 | 0.00 | 0.00 | -233.52K | 325.47K | -63.72K | -419.95K | 1.36K |
| Net Income | -311.73K | -1.29M | -3.21M | -1.76M | -3.05M | -2.77M | -6.01M | -4.27M | -5.04M | -5.20M | -28.57K | -3.36M | -3.49M | -2.40M | 79.66K | -170.27K | -601.19K | -290.44K | -427.52K | -984.40K | -105.07K |
| Net Income Ratio | -88.13% | -364.20% | -906.17% | -498.63% | -861.72% | -2,286.34% | 0.00% | 0.00% | 0.00% | 0.00% | -0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.03 | -0.10 | -0.07 | -0.13 | -0.13 | -0.32 | -0.54 | -0.89 | -1.02 | -0.01 | -0.79 | -1.00 | -1.11 | 0.63 | -1.35 | -4.95 | -0.08 | -2.96 | -0.30 | -0.04 |
| EPS Diluted | -0.01 | -0.03 | -0.10 | -0.07 | -0.13 | -0.13 | -0.32 | -0.54 | -0.89 | -1.02 | -0.01 | -0.79 | -1.00 | -1.11 | 0.63 | -1.35 | -4.95 | -0.08 | -2.96 | -0.30 | -0.04 |
| Weighted Avg Shares Out | 59.24M | 37.77M | 32.49M | 26.96M | 24.11M | 21.85M | 18.68M | 7.95M | 5.69M | 5.09M | 4.52M | 4.27M | 3.49M | 2.16M | 125.88K | 125.88K | 121.53K | 3.49M | 144.36K | 3.28M | 2.84M |
| Weighted Avg Shares Out (Dil) | 59.24M | 37.77M | 32.49M | 26.96M | 24.11M | 21.85M | 18.68M | 7.95M | 5.69M | 5.09M | 4.52M | 4.27M | 3.49M | 2.16M | 125.88K | 125.88K | 121.53K | 3.49M | 144.36K | 3.28M | 2.84M |
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male...
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC / ACCESSWIRE / October 12, 2021 / RepliCel Life Sciences Inc. (OTC...
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing RepliCel signs an Option to License agreement related to a filed US...
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a...
RepliCel Adds Independent Director
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to...
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan VANCOUVER, BC / ACCESSWIRE / May 19,...
RepliCel Announces Record Year in Patents Granted
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company...
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"),...
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today...
RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- RepliCel Life Sciences Inc. (OTC PK : REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today its intent to enter into...
Source: https://incomestatements.info
Category: Stock Reports